{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T05:58:59Z","timestamp":1693115939567},"reference-count":0,"publisher":"Dustri-Verlgag Dr. Karl Feistle","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CP"],"published-print":{"date-parts":[[2001,12,1]]},"DOI":"10.5414\/cpp39546","type":"journal-article","created":{"date-parts":[[2011,3,25]],"date-time":"2011-03-25T08:40:00Z","timestamp":1301042400000},"page":"546-550","source":"Crossref","is-referenced-by-count":5,"title":["Alfacalcidol in the therapy of renal bone disease"],"prefix":"10.5414","volume":"39","author":[{"given":"M.","family":"Ritzerfeld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Klasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3374","container-title":["Int. Journal of Clinical Pharmacology and Therapeutics"],"original-title":[],"language":"en","deposited":{"date-parts":[[2013,9,6]],"date-time":"2013-09-06T10:24:59Z","timestamp":1378463099000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.dustri.com\/article_response_page.html?artId=6057&doi=10.5414\/CPP39546&L=0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12,1]]},"references-count":0,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2001]]}},"alternative-id":["39546"],"URL":"https:\/\/doi.org\/10.5414\/cpp39546","relation":{},"ISSN":["0946-1965"],"issn-type":[{"value":"0946-1965","type":"print"}],"subject":[],"published":{"date-parts":[[2001,12,1]]}}}